23 Oct 2012 17:23
e-Therapeutics plc ("e-Therapeutics" or the "Company")
23 October 2012
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Company received notification on 23 October 2012 that Novotech Investment Limited (NIL), a company of which Professor Malcolm Young (CEO) is a Director and in which he has options to subscribe for ordinary shares, had sold 25,000 ordinary shares in e-Therapeutics plc at £0.38 per share on 10 October 2012 and 40,000 ordinary shares in e-Therapeutics plc at £0.355 per share on 22 October 2012. Professor Malcolm Young is one of three directors in NIL and as such had no ability by himself to prevent NIL from selling shares. It is understood that NIL has disposed of the shares to enable NIL to discharge its obligations to third parties.
Following the sale, Professor Young's direct beneficial interest remains unchanged at 20,620,482 shares, representing 14.92% of the total issued share capital of the Company (of which 10,310,241 shares are held by Professor Young and 10,310,241 shares are held by Professor Young's wife). However, Professor Young's indirect holding relating to interests that he holds in NIL and Novotech Syndicate LLP has been reduced by 19,396 shares, and now stands at 403,148 shares, representing 0.29% of the total issued share capital of the Company.
Contacts:
e-Therapeutics plc
Daniel Elger
Tel: +44 (0)79 0991 5068
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Fred Walsh / Hannah Woodley / Grishma Patel
Tel: +44 (0) 20 7886 2500
www.panmure.com